This Nasal Spray Could Replace EpiPens - And Make Early Investors Rich - ARS Pharma (SPRY) Deep Dive

Undervalued And Overlooked Podcast 8 months ago

Description

In this episode, Mariusz Skonieczny sits down with Steve, aka Unemployed Value Degen, to talk small caps, market cycles, and one life-saving biotech stock that could change everything: ARS Pharmaceuticals ($SPRY) — the company behind a revolutionary epinephrine nasal spray that could replace EpiPens for millions of people with severe allergies.

💊 We cover:

Why EpiPens are outdated — and how a needle-free nasal spray could dominate a multi-billion-dollar market

The team behind $SPRY, who previously took Narcan nasal spray to 95% market share

How Abacus Global Management ($ABL) is quietly building a multi-billion-dollar business in the life settlements market

Why small-cap cyclicals and chemical companies may be the most mispriced opportunities in 2025

🔥 Whether you're into biotech, deep-value investing, or small-cap turnarounds — this one is for you.

📈 Timestamps:
00:00 – Intro: Meet “Unemployed Value Degen”
02:00 – His investment philosophy: finding value in chaos
08:30 – Why he’s bullish on U.S. chemical stocks
12:00 – The $SPRY nasal spray that could replace EpiPens
18:00 – The life settlements goldmine: Abacus Global ($ABL)
24:00 – How to find small-cap gems before Wall Street does

💬 Follow the guests:

Mariusz Konieczny – YouTube Channel

Steve (Unemployed Value Degen) – Substack
| Twitter/X

#Investing #SmallCaps #Biotech #SPRY #AbacusGlobal #ValueInvesting #MariuszKonieczny #Epinephrine #NasalSpray #StocksToWatch #FinancePodcast

Sign up for my free email list and receive a free E-book, MicroCap Investor.: https://mailchi.mp/556515e42e7c/sign-up-for-mailing-list